<DOC>
	<DOCNO>NCT00369109</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor identify learn biomarkers related cancer . PURPOSE : This laboratory study collect skin biopsy specimens patient receive irinotecan gemcitabine advance solid tumor use study change DNA due treatment .</brief_summary>
	<brief_title>Skin Biopsies DNA Analysis Patients Receiving Irinotecan Gemcitabine For Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine level p-Chk1 phospho-histone 2AX ( p-H2AX ) , indicator DNA damage , possibly downstream pathway marker hair follicle skin biopsy patient treat gemcitabine hydrochloride irinotecan hydrochloride advance solid tumor . Secondary - Characterize method measurement ( immunohistochemistry ) . - Measure inter- intra-patient variability biomarker . - Partially characterize dynamic time course p-Chk1 p-H2AX administration DNA-damaging agent . OUTLINE : This multicenter study . Patients undergo collection 2 skin biopsy hair follicle 4 8 hour 4 6 hour start irinotecan hydrochloride gemcitabine hydrochloride treatment day 1 course 1 . Repeat biopsy take 4 , 6 , 8 hour start irinotecan hydrochloride gemcitabine hydrochloride day 1 2 successive course . Tissue examine immunohistochemistry possibly method change p-Chk1 pH2AX . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis advance solid tumor malignancy ( preferably colorectal , pancreatic , breast cancer ) Scheduled receive standard dose , weekly regimen either irinotecan hydrochloride gemcitabine hydrochloride PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : No DNAdamaging agent within past 13 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>